The stock of Boston Scientific Corp (NYSE:BSX) last traded at $104.80, up 0.65% from the previous session.
BSX stock price is now 5.62% away from the 50-day moving average and 15.18% away from the 200-day moving average. The market capitalization of the company currently stands at $155.05B.
With the price target maintained at $113, Needham recently Upgraded its rating from Hold to Buy for Boston Scientific Corp (NYSE: BSX). On January 10, 2025, Deutsche Bank Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $108, while ‘Needham’ rates the stock as ‘Hold’
In other news, Sorenson John Bradley, EVP, Global Operations sold 4,572 shares of the company’s stock on May 05 ’25. The stock was sold for $477,957 at an average price of $104.54. Upon completion of the transaction, the EVP, Global Operations now directly owns 18,705 shares in the company, valued at $1.96 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01 ’25, Chairman, President & CEO Mahoney Michael F sold 164,443 shares of the business’s stock. A total of $16,851,974 was realized by selling the stock at an average price of $102.48. This leaves the insider owning 1,535,706 shares of the company worth $160.94 million. A total of 0.47% of the company’s stock is owned by insiders.
During the past 12 months, Boston Scientific Corp has had a low of $71.88 and a high of $107.17. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 1.45, and a quick ratio of 0.88.
The net profit margin was 11.58% and return on equity was 9.65% for BSX. The company reported revenue of $4.66 billion for the quarter, compared to $3.86 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 20.93 percent.
